[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Silvia Ulrich\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100656307","phase-2-the-effect-of-additive-on-demand-sildenafil-vs-dextrose-candy-on-maximum-exercise-capacity-in-pulmonary-arterial-hypertension-100656307",false,"NCT07824674","The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension","The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension: A Randomized, Cross-Over Trial.","Pocket-PH","Inclusion Criteria:\n\n* Signed Informed consent\n* Age 18 - 80 years (both sexes)\n* Pulmonary hypertension (PH) class I (PAH) previously diagnosed according to ESC\u002FERS 2022\u002F2019 guidelines (mPAP ≥ 20 mmHg, PVR ≥ 2 WU, PAWP ≤ 15 mmHg) during diagnostic right-heart catheterization.\n* Stable condition, on the same PH-medication for \\>4 weeks\n\nExclusion Criteria:\n\n* Severe resting hypoxia (PaO2 \\\u003C7.3 kPa)\n* Moderate-to-severe chronic obstructive or restrictive pulmonary disease (FEV1 ≤ 60% predicted, FVC ≤ 60% predicted)\n* Women with known pregnancy or breast feeding\n* Other clinically significant concomitant disease states (e.g., severe renal or hepatic disease, unstable cardiovascular disease, etc.)\n* Concurrent medication with:\n\n  * Nitric oxide donors (molsidomine, nicrorandil, etc.)\n  * Soluble guanylate cyclase stimulators (riociguat)\n  * Potent CYP3A4 inhibitors (azoles, clarithromycin, protease inhibitors)\n* History of anterior ischemic optic neuropathy or hereditary retinal disease\n* Participation in another study with investigational drug with potential influence the study data within the 30 days preceding and during the present study.\n* Known allergies or hypersensitivity to sildenafil 20mg (Revatio 20mg) or dextrose candy (Dextroenergy) including any of its components","ALL","18 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The goal of this clinical study is to investigate whether the additional intake of sildenafil 20mg on top of standard medical treatment results in a benefit on maximum exercise workload (Wmax) in patients with pulmonary arterial hypertension (PAH).",[29],"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)",[31,32,33,34,35,36,37],"Sildenafil","Pulmonary Arterial Hypertension","Cardiopulmonary Testing","RCT","CPET","CWRET","Pill-In-The-Pocket","RECRUITING","2026-09-12",{"date":41,"type":42},"2026-09-17","ACTUAL",{"date":44,"type":22},"2026-09",{"date":46,"type":22},"2028-12",{"name":48,"class":49},"Silvia Ulrich","OTHER",""]